Primary signet ring cell carcinoma of the urinary bladder is a relatively rare histological variant of mucus-producing adenocarcinoma usually of poor prognosis. We report two cases of primary bladder signet ring carcinoma. The first patient underwent a radical cystectomy with ileal conduit (pT3bN1M0), radiotherapy, and chemotherapy (M-VAC regimen) and subsequently expired 37 months after surgery. The other was initially diagnosed with peritoneal metastasis from the primary bladder signet ring cell carcinoma and was treated with partial cystectomy (pT3bNOM1 Primary signet ring cell carcinoma of the urinary bladder is an extremely rare variant of adenocarcinoma that was first described by Saphir 1 in 1955. This tumor initially presents as a high-grade, high-stage lesion, because the neoplasm diffusely invades the bladder wall without forming intraluminal growth.As a result, patients have no specific symptoms, which leads to delayed diagnosis and poor prognosis. 2 We present 2 cases of primary signet ring cell carcinoma of the urinary bladder with a brief review of the current literature. CASE REPORTS CASE 1A 35-year-old man was admitted after experiencing painless gross hematuria for 3 months. The patient had no concomitant medical history or familial history of any malignancy. Laboratory data were within the normal ranges except for many red
Purpose: Bacillus Calmette-Guerin (BCG) immunotherapy is the treatment of choice for adjuvant therapy of superficial bladder cancer. The outcomes of a 6 week course of BCG immunotherapy was compared with those of a modified 6+3 maintenance therapy. Materials and Methods: Between January 2001 and June 2007, 123 patients with a superficial bladder cancer were treated with a transurethral resection of the bladder tumor (TURBT) and intravesical BCG. For the 93 patients, BCG was administered over a six week course. For the remaining 30 patients, BCG was administered for six weeks followed by three weekly instillations at 3, 6, 12, 18, 24 and 36 months. The recurrence rate, time to recurrence and progression rate were assessed and analyzed. Results: In the six week therapy group, the overall recurrence rate, mean recurrence interval and median follow up was 31.2% (29/93), 15.9 months and 19.4 months, respectively. The recurrence rate according to stage and grade was 27.6% (8/29), 33.9% (21/62) and 0% (0/2) on Ta, T1 and carcinoma in situ (CIS), respectively, and 29.6% (21/71), 40% (8/20) in low grade and high grade, respectively. Five cases in the T1 high grade and 1 case in T1 low grade group progressed to T2. In maintenance therapy, the overall recurrence rate, mean recurrence interval and median follow up was 16.7% (5/30), 16.4 months and 24.8 months, respectively. The recurrence rate according to stage and grade was 14.3% (1/7), 14.3% (3/21) and 50% (1/2) on Ta, T1, CIS, respectively, and 15.0% (3/20), 12.5% (1/8) in low grade and high grade, respectively. One case in the CIS sub group progressed to T4a. Conclusions: These results show a lower recurrence rate in the modified 6+3 maintenance therapy group than in the 6 week therapy group. Therefore, modified 6+3 maintenance therapy is more effective for preventing a recurrence in a superficial bladder cancer than 6 week therapy. (Korean J Urol 2008;49:703-708)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.